The total glaucoma market was estimated to be $2.6bn across the seven major markets in 2016 and this is expected to grow to $3.8bn in 2026, at a compound annual growth rate (CAGR) of 4.1%, according to GlobalData, a leading international data and analytics company.

The company’s latest report: ‘PharmaPoint: Glaucoma’ revealed growth will be driven by the launch of pipeline products, with five new products expected to enter the glaucoma market during the forecast period. These products include a first-in-class drug, Santen’s DE-117; one drug with an undisclosed MOA; Aerie’s fixed-dose combination therapy, Roclatan; and two sustained-release (SR) implants.